Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAZEPPA: Maintenance Olaparib or Selumetinib + Durvalumab in Metastatic Pancreatic Adenocarcinoma
NCT04348045Phase 2Active, not recruiting
- Sponsor
- GERCOR
- Start
- Dec 2020
- Primary completion
- Jun 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, durvalumab, selumetinib in pancreatic adenocarcinoma (PDAC), sponsored by GERCOR. Started Dec 2020; status: active, not recruiting.
02
Drugs
olaparibdurvalumabselumetinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04348045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04348045.